PharmTech Poll Results: How do you define 'PAT'? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Poll Results: How do you define 'PAT'?


Untitled Document

PharmTech Poll Results: How do you define ‘PAT,’ or ‘Process Analytical Technology’?

Thanks to all of you who participated in our poll! Here are a few of your answers, followed by the definition of ‘process analytical technology ’ given by FDA.

Your answers

1. “I believe that PAT is well-defined in their Guidance document in IV. PAT Framework, ‘a system for designing, analyzing, and controlling manufacturing ... with the goal of assuring final product quality. Analyzing is not just lab analysis but also includes statistical analysis of the data.’”

2. “PAT means incorporating analytical steps into each stage of the manufacturing process and using the results to evaluate and control the process in real time.”

According to FDA

FDA defines process analytical technology in its Guidance for Industry, as:

“Process Analytical Technology is: a system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality.  

“It is important to note that the term analytical in PAT is viewed broadly to include chemical, physical, microbiological, mathematical, and risk analysis conducted in an integrated manner.” The guidance is available here.

To add your definition, click here.

Click here to visit our poll archive.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here